A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Recruiting

Phase 2

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Sponsor:

Cybrexa Therapeutics

Code:

NCT06315491

Conditions

Platinum-resistant Ovarian Cancer

Refractory Ovarian Carcinoma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CBX-12

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-12. This information was provided to ClinicalTrials.gov by Cybrexa Therapeutics on 2025-03-12.